This HTML5 document contains 35 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n25http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00023/identifier/genbank/
dctermshttp://purl.org/dc/terms/
n5http://linked.opendata.cz/resource/drugbank/drug/DB00023/identifier/uniprotkb/
n13http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n21http://linked.opendata.cz/resource/mesh/concept/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00023/identifier/wikipedia/
n9http://linked.opendata.cz/resource/drugbank/company/
n8http://linked.opendata.cz/resource/drugbank/dosage/
n4http://linked.opendata.cz/resource/drugbank/drug/DB00023/identifier/pharmgkb/
n16http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n24http://linked.opendata.cz/resource/drugbank/drug/DB00023/identifier/drugbank/
n15http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n7http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n20http://linked.opendata.cz/ontology/mesh/
n6http://linked.opendata.cz/ontology/drugbank/
n18http://www.drugs.com/cdi/
n10http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n12http://linked.opendata.cz/resource/atc/
n11http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00023
rdf:type
n6:Drug
n6:description
L-asparagine amidohydrolase from E. coli
n6:dosage
n8:271B3FE9-363D-11E5-9242-09173F13E4C5
n6:generalReferences
# Appel IM, van Kessel-Bakvis C, Stigter R, Pieters R: Influence of two different regimens of concomitant treatment with asparaginase and dexamethasone on hemostasis in childhood acute lymphoblastic leukemia. Leukemia. 2007 Jun 7;. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17554375 # http://www.google.com/patents/EP2046369A2
n6:group
approved
n6:halfLife
8-30 hrs
n6:indication
For treatment of acute lympocytic leukemia and non-Hodgkins lymphoma
owl:sameAs
n15:DB00023 n16:DB00023
dcterms:title
Asparaginase
adms:identifier
n4:PA448492 n5:P37595 n22:Asparaginase n23:U00096 n24:DB00023
n6:mechanismOfAction
Asparaginase converts asparagine to aspartic acid and ammonia. It facilitates production of oxaloacetate which is needed for general cellular metabolism. Some malignant cells lose the ability to produce asparagine and so the loss of exogenous sources of asparagine leads to cell death.
n6:packager
n9:271B3FE7-363D-11E5-9242-09173F13E4C5 n9:271B3FE5-363D-11E5-9242-09173F13E4C5 n9:271B3FE6-363D-11E5-9242-09173F13E4C5
n6:synonym
Putative L-asparaginase precursor L-asparagine amidohydrolase
n11:hasAHFSCode
n13:10-00-00
n6:synthesisReference
Masao Nambu, "Process for producing immobilized L-asparaginase preparations for the therapy of leukemia." U.S. Patent US4617271, issued January, 1977.
n20:hasConcept
n21:M0001815
foaf:page
n18:asparaginase.html n25:asparaginase.htm
n6:Molecular-Formula
n10:271B3FED-363D-11E5-9242-09173F13E4C5
n6:Molecular-Weight
n10:271B3FEC-363D-11E5-9242-09173F13E4C5
n11:hasATCCode
n12:L01XX02
n6:affectedOrganism
Humans and other mammals
n6:casRegistryNumber
9015-68-3
n6:category
n6:containedIn
n7:271B3FE8-363D-11E5-9242-09173F13E4C5
n6:Hydrophobicity
n10:271B3FEA-363D-11E5-9242-09173F13E4C5
n6:Isoelectric-Point
n10:271B3FEB-363D-11E5-9242-09173F13E4C5